Thus, several PD-1 and PD-L1 inhibitors have been or are being tested for use in several different cancers such as non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and Hodgkin lymphoma. Here, CD274 is linked to head and neck squamous cell carcinoma.